Isomorphic Labs announced on 20 January 2026 a cross-modality, multi-target research collaboration with Johnson & Johnson (legal entity given as Janssen Biotech, Inc.), under which, as it states, Isomorphic is responsible for in silico predictions and design and Johnson & Johnson for experimental assays and advancing programmes.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.